全文获取类型
收费全文 | 286篇 |
免费 | 21篇 |
出版年
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 9篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 15篇 |
2017年 | 12篇 |
2016年 | 13篇 |
2015年 | 20篇 |
2014年 | 11篇 |
2013年 | 25篇 |
2012年 | 28篇 |
2011年 | 21篇 |
2010年 | 10篇 |
2009年 | 10篇 |
2008年 | 16篇 |
2007年 | 11篇 |
2006年 | 14篇 |
2005年 | 10篇 |
2004年 | 7篇 |
2003年 | 5篇 |
2002年 | 6篇 |
2001年 | 1篇 |
2000年 | 5篇 |
1999年 | 11篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1995年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有307条查询结果,搜索用时 15 毫秒
121.
Lacroix-Desmazes S Wootla B Dasgupta S Delignat S Bayry J Reinbolt J Hoebeke J Saenko E Kazatchkine MD Friboulet A Christophe O Nagaraja V Kaveri SV 《Journal of immunology (Baltimore, Md. : 1950)》2006,177(2):1355-1363
Factor VIII (FVIII) inhibitors are anti-FVIII IgG that arise in up to 50% of the patients with hemophilia A, upon therapeutic administration of exogenous FVIII. Factor VIII inhibitors neutralize the activity of the administered FVIII by sterically hindering its interaction with molecules of the coagulation cascade, or by forming immune complexes with FVIII and accelerating its clearance from the circulation. We have shown previously that a subset of anti-factor VIII IgG hydrolyzes FVIII. FVIII-hydrolyzing IgG are detected in over 50% of inhibitor-positive patients with severe hemophilia A, and are not found in inhibitor-negative patients. Although human proficient catalytic Abs have been described in a number of inflammatory and autoimmune disorders, their pathological relevance remains elusive. We demonstrate here that the kinetics of FVIII degradation by FVIII-hydrolyzing IgG are compatible with a pathogenic role for IgG catalysts. We also report that FVIII-hydrolyzing IgG from each patient exhibit multiple cleavage sites on FVIII and that, while the specificity of cleavage varies from one patient to another, catalytic IgG preferentially hydrolyze peptide bonds containing basic amino acids. 相似文献
122.
Prins RM Craft N Bruhn KW Khan-Farooqi H Koya RC Stripecke R Miller JF Liau LM 《Journal of immunology (Baltimore, Md. : 1950)》2006,176(1):157-164
Immunotherapy represents an appealing option to specifically target CNS tumors using the immune system. In this report, we tested whether adjunctive treatment with the TLR-7 agonist imiquimod could augment antitumor immune responsiveness in CNS tumor-bearing mice treated with human gp100 + tyrosine-related protein-2 melanoma-associated Ag peptide-pulsed dendritic cell (DC) vaccination. Treatment of mice with 5% imiquimod resulted in synergistic reduction in CNS tumor growth compared with melanoma-associated Ag-pulsed DC vaccination alone. Continuous imiquimod administration in CNS tumor-bearing mice, however, was associated with the appearance of robust innate immune cell infiltration and hemorrhage into the brain and the tumor. To understand the immunological mechanisms by which imiquimod augmented antitumor immunity, we tested whether imiquimod treatment enhanced DC function or the priming of tumor-specific CD8+ T cells in vivo. With bioluminescent, in vivo imaging, we determined that imiquimod dramatically enhanced both the persistence and trafficking of DCs into the draining lymph nodes after vaccination. We additionally demonstrated that imiquimod administration significantly increased the accumulation of tumor-specific CD8+ T cells in the spleen and draining lymph nodes after DC vaccination. The results suggest that imiquimod positively influences DC trafficking and the priming of tumor-specific CD8+ T cells. However, inflammatory responses induced in the brain by TLR signaling must also take into account the local microenvironment in the context of antitumor immunity to induce clinical benefit. Nevertheless, immunotherapeutic targeting of malignant CNS tumors may be enhanced by the administration of the innate immune response modifier imiquimod. 相似文献
123.
124.
Todd M. Brusko Richard C. Koya Shirley Zhu Michael R. Lee Amy L. Putnam Stephanie A. McClymont Michael I. Nishimura Shuhong Han Lung-Ji Chang Mark A. Atkinson Antoni Ribas Jeffrey A. Bluestone 《PloS one》2010,5(7)
Background
Therapies directed at augmenting regulatory T cell (Treg) activities in vivo as a systemic treatment for autoimmune disorders and transplantation may be associated with significant off-target effects, including a generalized immunosuppression that may compromise beneficial immune responses to infections and cancer cells. Adoptive cellular therapies using purified expanded Tregs represents an attractive alternative to systemic treatments, with results from animal studies noting increased therapeutic potency of antigen-specific Tregs over polyclonal populations. However, current methodologies are limited in terms of the capacity to isolate and expand a sufficient quantity of endogenous antigen-specific Tregs for therapeutic intervention. Moreover, FOXP3+ Tregs fall largely within the CD4+ T cell subset and are thus routinely MHC class II-specific, whereas class I-specific Tregs may function optimally in vivo by facilitating direct tissue recognition.Methodology/Principal Findings
To overcome these limitations, we have developed a novel means for generating large numbers of antigen-specific Tregs involving lentiviral T cell receptor (TCR) gene transfer into in vitro expanded polyclonal natural Treg populations. Tregs redirected with a high-avidity class I-specific TCR were capable of recognizing the melanoma antigen tyrosinase in the context of HLA-A*0201 and could be further enriched during the expansion process by antigen-specific reactivation with peptide loaded artificial antigen presenting cells. These in vitro expanded Tregs continued to express FOXP3 and functional TCRs, and maintained the capacity to suppress conventional T cell responses directed against tyrosinase, as well as bystander T cell responses. Using this methodology in a model tumor system, murine Tregs designed to express the tyrosinase TCR effectively blocked antigen-specific effector T cell (Teff) activity as determined by tumor cell growth and luciferase reporter-based imaging.Conclusions/Significance
These results support the feasibility of class I-restricted TCR transfer as a promising strategy to redirect the functional properties of Tregs and provide for a more efficacious adoptive cell therapy. 相似文献125.
Dana Bereket Dalga Koya Alemayehu Nana Song Xiaowei Lin Jingquan 《Plasmonics (Norwell, Mass.)》2020,15(6):1977-1988
Plasmonics - Breaking the morphological and compositional symmetries of metallic nanoparticle (NP) dimers provides a novel approach to modulate plasmon coupling between the NPs. In this study, we... 相似文献
126.
Raj K. Diraviya Aeby Greta S. Mathews G. Williams Gareth J. Caldwell Jamie M. Laju R. L. Bharath M. Selva Kumar P. Dinesh Arasamuthu A. Asir N. Gladwin Gnana Wedding Lisa M. Davies Andrew J. Moritsch Monica M. Edward J. K. Patterson 《Coral reefs (Online)》2021,40(4):1029-1044
Coral Reefs - We used a 12-yr data set of benthic cover (2005–2017), spanning two bleaching events, to assess changes in benthic cover and coral community composition along 21 islands within... 相似文献
127.
Motoi Suzuki Hiroyuki Yoshimine Yoshitaka Harada Naho Tsuchiya Ikumi Shimada Koya Ariyoshi Kenichiro Inoue 《PloS one》2013,8(1)
Background
Influenza vaccine effectiveness (VE) studies are usually conducted by specialized agencies and require time and resources. The objective of this study was to estimate the influenza VE against medically attended influenza using a test-negative case-control design with rapid influenza diagnostic tests (RIDT) in a clinical setting.Methods
A prospective study was conducted at a community hospital in Nagasaki, western Japan during the 2010/11 influenza season. All outpatients aged 15 years and older with influenza-like illnesses (ILI) who had undergone RIDT were enrolled. A test-negative case-control design was applied to estimate the VEs: the cases were ILI patients with positive RIDT results and the controls were ILI patients with negative RIDT results. Information on patient characteristics, including vaccination histories, was collected using questionnaires and medical records.Results
Between December 2010 and April 2011, 526 ILI patients were tested with RIDT, and 476 were eligible for the analysis. The overall VE estimate against medically attended influenza was 47.6%, after adjusting for the patients'' age groups, presence of chronic conditions, month of visit, and smoking and alcohol use. The seasonal influenza vaccine reduced the risk of medically attended influenza by 60.9% for patients less than 50 years of age, but a significant reduction was not observed for patients 50 years of age and older. A sensitivity analysis provided similar figures.Conclusion
The test-negative case-control study using RIDT provided moderate influenza VE consistent with other reports. Utilizing the commonly used RIDT to estimate VE provides rapid assessment of VE; however, it may require validation with more specific endpoint. 相似文献128.
Ramu Manjula Sruthi Unni Gareth S. A. Wright Srinivas Bharath M. M. 《Journal of biomolecular structure & dynamics》2013,31(15):3936-3946
AbstractFormation of Cu, Zn superoxide dismutase 1 (SOD1) protein inclusions within motor neurons is one of the principal characteristics of SOD1-related amyotrophic lateral sclerosis (ALS). A hypothesis as to the nature of SOD1 aggregation implicates oxidative damage to a solvent-exposed tryptophan as causative. Here, we chart the discovery of a phenanthridinone based compound (Lig9) from the NCI Diversity Set III by rational methods by in silico screening and crystallographic validation. The crystal structure of the complex with SOD1, refined to 2.5 Å, revealed that Lig9 binds the SOD1 β-barrel in the β-strand 2 and 3 region which is known to scaffold SOD1 fibrillation. The phenanthridinone moiety makes a substantial π–π interaction with Trp32 of SOD1. The compound possesses a significant binding affinity for SOD1 and inhibits oxidation of Trp32; a critical residue for SOD1 aggregation. Thus, Lig9 is a good candidate from which to develop a new library of SOD1 aggregation inhibitors through protection of Trp32 oxidation.Communicated by Ramaswamy H. Sarma 相似文献
129.
Kazuya Hayashi Danji Fukushima Koya Mogi 《Bioscience, biotechnology, and biochemistry》2013,77(10):1171-1178
Some physicochemical properties and amino acid composition of alkaline proteinase from Aspergillus sojae were found to be as follows: The isoelectric point was at pH 5.1. The molecular weight was 25,500 using the Sheraga-Mandelkern’s formula, based upon the values of the sedimentation coefficient , the intrinsic viscosity ([η] = 0.027 dl/g), and the partial specific volume . The enzyme contains 16.8% of nitrogen and is composed of 250 residues of amino acid; Asp31 Glu19, Gly27, Ala32, Val18, Leu14, Ile14, Ser28, Thr18, , Met2, Pro6, Phe7, Tyr8, Trp2, His5, Lys14, Arg3, (amide-NH3)20. 相似文献
130.
Yoshinori Ozawa Kazuo Suzuki Takeji Mizunuma Koya Mogi 《Bioscience, biotechnology, and biochemistry》2013,77(6):1285-1293
An aminopeptidase was purified from Aspergillus sojae X–816. The molecular weight of the enzyme was estimated to be 220,000. The isoelectric point was at pH 5.3. The optimum pH for l-leucylglycylglycine was 7.5. The enzyme was stable up to 37°C against temperature treatment for 15 min. Some chelating agents inhibited the enzyme activity. The Km value for l-leucylglycylglycine at pH 7.5 and 37°C was 45 mm. The Km value for l-leucyl-β-naphthylamide at pH 7.0 and 37°C was 2.2 mm. 相似文献